4.7 Article

Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease

期刊

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 13, 期 6, 页码 1042-+

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2013.09.006

关键词

Crohn's Disease; Therapy; Prevention and Control; Mucosal Healing; Treat to Target

资金

  1. Abbott Laboratories
  2. Ferring
  3. MSD Pharma
  4. Abbott (AbbVie)
  5. Actogenix
  6. Albireo Pharma
  7. Amgen
  8. Astra Zeneca
  9. Athersys
  10. Avaxia Biologics Inc
  11. Axcan
  12. Boehringer-Ingelheim France
  13. Bristol-Myers Squibb
  14. Celgene
  15. Centocor
  16. Elan/Biogen
  17. Ferring Pharma A/S
  18. Genentech
  19. GiCare Pharma
  20. Gilead
  21. Given Imaging Inc
  22. GSK
  23. Ironwood Pharma
  24. JnJ/Janssen
  25. Merck
  26. Millennium
  27. Nektar
  28. Novonordisk
  29. Prometheus Therapeutics and Diagnostics
  30. Pfizer
  31. Salix Pharma
  32. Serono
  33. Shire
  34. Sigmoid Pharma
  35. Synergy Pharma Inc
  36. Takeda
  37. Teva Pharma
  38. Tillotts
  39. UCB Pharma
  40. Unity Pharmaceuticals
  41. Warner-Chilcott
  42. Wyeth
  43. Zealand Pharm
  44. Zyngenia
  45. Abbott
  46. CombinatoRx
  47. Milllennium
  48. Novartis
  49. Protein Design Labs
  50. AbbVie
  51. Janssen
  52. BMS
  53. Roche
  54. Astellas
  55. UCB
  56. Mitsubishi
  57. Norgine
  58. Tillots
  59. Vifor
  60. Therakos
  61. Pharmacosmos
  62. Pilege
  63. UCB-Pharma
  64. Hospira
  65. Astellas Pharma
  66. Baxter
  67. Bristol-Meyers Squibb
  68. Coronado Biosciences
  69. Elan Pharmaceuticals
  70. Eli Lilly
  71. Ferring Pharmaceuticals
  72. Glaxo Smith Kline
  73. Ironwood Pharmaceuticals
  74. Meda Pharmaceuticals
  75. Millennium Pharmaceuticals
  76. Novo Nordisk A/S
  77. NPS Pharmaceuticals
  78. Prometheus Laboratories
  79. Receptos
  80. Sanofie
  81. Santarus
  82. Shire Pharmaceuticals
  83. S. L. A. Pharma (UK) Limited
  84. Vertex
  85. Warner Chilcott UK Limited
  86. Prometheus Labs
  87. ActoGeniX NV
  88. AGI Therapeutics, Inc
  89. Alba Therapeutics Corporation
  90. Albireo
  91. Alfa Wasserman
  92. AM-Pharma BV
  93. Anaphore
  94. Athersys, Inc
  95. Atlantic Healthcare Limited
  96. Aptalis
  97. BioBalance Corporation
  98. Boehringer-Ingelheim Inc
  99. Celek Pharmaceuticals
  100. Cellerix SL
  101. Cerimon Pharmaceuticals
  102. ChemoCentryx
  103. CoMentis
  104. Cosmo Technologies
  105. Cytokine Pharmasciences
  106. Eagle Pharmaceuticals
  107. Eisai Medical Research Inc
  108. EnGene, Inc
  109. Enteromedics
  110. Exagen Diagnostics, Inc
  111. Flexion Therapeutics, Inc
  112. Funxional Therapeutics Limited
  113. Genzyme Corporation
  114. Gilead Sciences
  115. Given Imaging
  116. Human Genome Sciences
  117. KaloBios Pharmaceuticals, Inc
  118. Lexicon Pharmaceuticals
  119. Lycera Corporation
  120. Merck Research Laboratories
  121. MerckSerono
  122. Nisshin Kyorin Pharmaceuticals Co, Ltd
  123. Optimer Pharmaceuticals
  124. Orexigen Therapeutics, Inc
  125. PDL Biopharma
  126. Procter
  127. Gamble
  128. ProtAb Limited
  129. Purgenesis Technologies, Inc
  130. Relypsa, Inc
  131. Salient Pharmaceuticals
  132. Salix Pharmaceuticals, Inc
  133. Schering Plough Corporation
  134. Sigmoid Pharma Limited
  135. Sirtris Pharmaceuticals, Inc (a GSK company)
  136. Targacept
  137. Teva Pharmaceuticals
  138. Tillotts Pharma AG
  139. TxCell SA
  140. Viamet Pharmaceuticals
  141. Vascular Biogenics Limited (VBL)
  142. Gamble Pharmaceuticals
  143. Zeria Pharmaceutical Co, Ltd

向作者/读者索取更多资源

The traditional management of Crohn's disease, which is based on progressive, step-wise treatment intensification with re-evaluation of response according to symptoms, does not improve long-term outcomes of Crohn's disease and places patients at risk for bowel damage. The introduction of novel therapies and the development of new approaches to treatment in rheumatoid arthritis led to better outcomes for patients. Prominent among these is a treat to target strategy that is based on regular assessment of disease activity by using objective clinical and biological outcome measures and the subsequent adjustment of treatments. This approach is complementary to the concept of early intervention in high-risk patients. This review evaluates current literature on this topic and proposes a definition for the concept of treating to targets for Crohn's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据